Skip to content

Affect-regulatory Characteristics of Deceptive Placebos

The Influence of Expectations on Affect-regulatory Characteristics of Deceptive Placebos: An Experimental Investigation

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05372744
Enrollment
127
Registered
2022-05-13
Start date
2022-05-25
Completion date
2022-07-31
Last updated
2023-06-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Depression, Social Anxiety

Brief summary

The study tries to identify whether specifically framed expectations, induced with an active placebo nasal-spray, have effects on affective regulation processes and rumination.

Detailed description

Healthy volunteers are informed that a new application method for an antidepressant, specialized on positively influencing the experience of aversive emotional states would be tested. They will randomly be assigned to a no treatment control group (not taking a placebo) or to one of the two treatment groups: Participants will be taking the antidepressant (which is in fact an active placebo) which will either protect them from experiencing intense emotional reactions and rumination (anticipatory group) or help them to regulate emotional states quicker as well as to distance themselves from ruminative thoughts (reactive group). Then, an aversive emotional state is induced by an autobiographical recall of events which made the participants feel inadequate, bashful, and ashamed. Currently experienced shame as well as state rumination are assessed before and after the negative recall task.

Interventions

OTHERActive Placebo labelled as antidepressant

Participants receive an active nasal spray that is in fact a placebo with a specific framing in regards to its affect-regulatory characteristics, respectively.

Sponsors

Philipps University Marburg
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
Yes

Inclusion criteria

* healthy volunteers * fluent in German language

Exclusion criteria

* mental disorders * allergic to capsaicin * allergic to sesame oil * intake of psychopharmacological drugs in the last four weeks * intake of illegal drugs in the last two weeks * consumption of alcohol in the last twelve hours * students in medicine, pharmacy, or psychology * completed studies in medicine, pharmacy or psychology * current pregnancy or lactation * cardio vascular disease * kidney disease * liver disease

Design outcomes

Primary

MeasureTime frameDescription
Change in Experienced Shame (Experienced Shame Scale, 'ESS')At baseline and after autobiographical recall. Each assessment is taking 5 minutes, in total 10 minutes.German questionnaire of 11 items, e.g., physical phenomena: feeling very warm--- very cold; pale---flushed; emotional phenomena: feeling good---bad, clear---confused, calm---highly aroused , social phenomena: feeling like hiding---being sociable, talking---being quiet All Items will be rated on a Likert scale from 1 (= strongly disagree) to 7 (= strongly agree)

Secondary

MeasureTime frameDescription
Change in State Rumination (Fragebogen zur Erfassung aktueller Ruminationsneigung)At baseline and after the rumination induction. Each assessment is taking 5 Minutes, in total 10 minutes.German questionnaire of 10 Items, e.g.: I get lost in ruminative thoughts., I am present in this situation., My thoughts are focused on the past.. All Items will be rated on a Likert scale from 0 (not at all) to 10 (very much).

Countries

Germany

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026